Since heme synthesis is primarily driven by ALAS2 in bone marrow erythroid precursors, downregulation of ALAS1 via inhibition of HO in bone marrow would likely have minimal therapeutic benefit for EPP. This evidence concerns the gene HMOX1 and autosomal erythropoietic protoporphyria.